Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.

MLA

Haddad, Fadi G., et al. “Results of Ponatinib as Frontline Therapy for Chronic Myeloid Leukemia in Chronic Phase.” Cancer (0008543X), vol. 130, no. 19, Oct. 2024, pp. 3344–52. EBSCOhost, https://doi.org/10.1002/cncr.35384.

APA

Haddad, F. G., Sasaki, K., Nasr, L., Short, N. J., Kadia, T., Dellasala, S., Cortes, J., Nicolini, F. E., Issa, G. C., Jabbour, E., & Kantarjian, H. (2024). Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer (0008543X), 130(19), 3344–3352. https://doi.org/10.1002/cncr.35384

Chicago

Haddad, Fadi G., Koji Sasaki, Lewis Nasr, Nicholas J. Short, Tapan Kadia, Sara Dellasala, Jorge Cortes, et al. 2024. “Results of Ponatinib as Frontline Therapy for Chronic Myeloid Leukemia in Chronic Phase.” Cancer (0008543X) 130 (19): 3344–52. doi:10.1002/cncr.35384.